Phagos raises €25 million in a Series A funding round to accelerate the deployment of its pioneering phage-based veterinary treatments, driven by a unique blend of microbiology and AI technology.

Target Company Overview

Phagos, founded in 2021 by Alexandros Pantalis and Dr. Adèle James, has achieved a significant milestone by becoming the first company authorized to market personalized veterinary phage-based treatments in the European Union. The company is pioneering a new era in combating bacterial diseases through the innovative use of bacteriophages, which serve as a natural alternative to antibiotics. These phage-based therapies are driven by Phagos' unique platform that integrates microbiology and artificial intelligence (AI) for the development of targeted and effective treatments.

Bacterial diseases are a leading cause of human mortality and significantly impact animal health, leading to substantial losses in agriculture. The emergence of antimicrobial resistance poses a growing threat; more than 30% of antibiotics used in livestock are no longer effective. Phagos aims to address these pressing challenges through the deployment of its veterinary solutions, with aspirations for future applications in human health.

Industry Overview in France

The landscape of veterinary medicine in France reflects a broader global trend towards alternative therapies, particularly as concerns over antibiotic resistance rise. As livestock and pet health are increasingly prioritized, the veterinary marke